U.S. Marketing-to-Sales Ratios of Select Injectable Insulin Drugs [1]
`
`Drug
`
`Launch Date [2]
`
`0
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`Years Since Launch
`
`25.7%
`394.3%
`65.4%
`
`113.7%
`7.7%
`
`44.2%
`13.6%
`
`63.0%
`13.8%
`
`30.7%
`17.8%
`
`65.0%
`10.5%
`1.5%
`
`0.1%
`7.5%
`
`40.7%
`4.5%
`1.0%
`
`0.3%
`5.8%
`
`16.6%
`5.9%
`0.4%
`
`0.3%
`2.6%
`
`9.1%
`2.1%
`1.2%
`
`1.5%
`2.9%
`
`3.6%
`0.7%
`1.5%
`
`1.4%
`0.8%
`
`3.3%
`
`4.9%
`
`2.7%
`0.9%
`
`0.2%
`3.5%
`
`0.2%
`1.4%
`
`37.0%
`12.6%
`7.2%
`32.6%
`9.1%
`
`17.6%
`0.1%
`2.0%
`13.1%
`4.2%
`
`10.9%
`
`0.7%
`9.7%
`2.4%
`
`6.9%
`2.0%
`
`3.1%
`1.4%
`
`3.2%
`2.0%
`
`7.2%
`0.9%
`
`4.2%
`1.5%
`
`2.9%
`4.6%
`
`3.4%
`4.3%
`
`4.3%
`4.8%
`
`5.7%
`44.3%
`0.0%
`8.9%
`6.1%
`0.0%
`39.8%
`
`93.8%
`0.0%
`12.1%
`9.8%
`0.0%
`69.7%
`
`0.9%
`0.6%
`52.6%
`0.0%
`1.1%
`2.3%
`0.0%
`24.6%
`
`0.2%
`0.9%
`15.3%
`5.0%
`0.0%
`0.6%
`0.0%
`11.8%
`
`1.2%
`3.5%
`2.8%
`7.8%
`0.0%
`1.1%
`1.6%
`11.0%
`
`2.4%
`2.4%
`28.3%
`7.2%
`5.6%
`2.4%
`1.0%
`17.4%
`
`1.6%
`11.1 %
`
`6.6%
`3.5%
`2.4%
`0.4%
`6.9%
`
`1.5%
`8.2%
`
`2.6%
`1.9%
`2.1%
`1.4%
`5.9%
`
`1.4%
`3.7%
`
`4.6%
`1.1%
`0.6%
`0.4%
`7.2%
`
`0.9%
`2.3%
`
`2.8%
`0.8%
`0.3%
`0.2%
`6.9%
`
`3.2%
`3.3%
`
`0.2%
`2.8%
`0.6%
`1.1%
`4.8%
`
`March 2018
`January 2006
`April 2009
`August 1996
`
`December 1998
`January 2008
`September 2017
`March 2016
`August 2001
`February 2003
`
`February 2000
`December 2000
`February 2006
`November 2006
`January 2008
`January 2008
`September 2002
`February 2003
`
`Fast-Acting
`
`Admelog Vial [3]
`Apidra Vial [4]
`Apidra Solo ST AR
`Humalog Vial [5]
`
`Humalog Pen [6]
`Humalog KwikPen [7]
`Humalog Jr. KwikPen
`Humulin R KwikPen [8]
`NovoLog Vial [9]
`NovoLog FlexPen
`
`Intermediate-Acting
`
`Humalog Pen Mix 75/25
`Humalog Mix 75/25 Vial [10]
`Humalog Pen Mix 50/50
`Humalog Mix 50/50 Vial [11]
`Humalog KwikPen 50/50
`Humalog KwikPen 75/25
`NovoLog FlexPen Mix 70/30 [12]
`Novo Log Mix 70/30 Vial [13]
`
`Long-Acting
`
`Basaglar KwikPen [14]
`Lantus Vial [15]
`Lantus SoloST AR
`
`Levemir FlexPen [16]
`Levemir Vial [17]
`Levemir FlexTouch
`
`December 2016
`April 2001
`July 2007
`
`February 2006
`February 2006
`May 2014
`
`20.5%
`
`10.9%
`
`0.1%
`387.3%
`7.9%
`
`5.6%
`19.6%
`2.6%
`
`8.3%
`289.5%
`3.2%
`
`13.5%
`3.0%
`
`6.0%
`189.1%
`0.4%
`
`9.9%
`6.6%
`
`3.9%
`117.8%
`0.3%
`
`8.6%
`2.1%
`
`2.3%
`37.7%
`0.2%
`
`8.6%
`2.2%
`
`4.3%
`39.4%
`
`11.5%
`2.5%
`
`4.1%
`31.4%
`
`6.3%
`1.6%
`
`6.1%
`14.3%
`
`5.6%
`0.3%
`
`4.4%
`9.8%
`
`6.2%
`0.5%
`
`5.1%
`0.3%
`
`5.7%
`
`2.8%
`
`Sanofi Exhibit 2205.001
`Mylan v. Sanofi
`IPR2018-01675
`
`

`

`Toujeo SoloSTAR [18]
`
`March 2015
`
`124.5%
`
`35.2%
`
`19.4%
`
`14.9%
`
`Toujeo Max SoloST AR [19]
`
`April 2018
`
`93.5%
`
`Tresiba FlexTouch [20]
`
`November 2015
`
`92.0%
`
`24.2%
`
`14.7%
`
`Source: IMS Health; "Levemir FlexPen to be Discontinued End of September," MPR, September 25, 2014, available at http://www.empr.com/news/levemir-flexpen-to-be-discontinued-end-of(cid:173)
`september/arlicle/373723/, accessed on October 30, 2018.
`Note:
`[1] Marketing data are only available for a subset of drugs in Exhibit 1. Marketing data are unavailable for all OptiClik products. Marketing is the sum of PROMOTIONS DOLLARS EXC SAMPLES
`and SAMPLES DOLLARS. PROMOTIONS DOLLARS EXC SAMPLES data span June 2002 through September 2018. SAMPLES DOLLARS data span January 2007 lhrough November
`2018. Data for first ten years after drug launch shown.
`[2] Launch dale is defined as the first month of IMS data with non-zero sales or prescriptions. For drugs launched prior to January 2001, launch dale is defined as the dale listed in the Product
`variable in the IMS data.
`[3] Admelog Vial consists of drugs listed as "Admelog" in the marketing data.
`[4] Apidra Vial consists of drugs listed as "Apidra" and "Insulin Glulisine" in the marketing data.
`[5] Humalog Vial consists of drugs listed as "Humalog," "Insulin Lispro," and "Lispro" in the marketing data.
`[6] Humalog Pen consists of drugs listed as "Humalog Pen" and "Lispro Pen" in the marketing data.
`[7] Humalog KwikPen consists of drugs listed as "Humalog KwikPen" and "Humalog KwikPen 200 U" in the marketing data.
`[8] Humulin R KwikPen consists of drugs listed as "Humulin R U-500 KwikPen" in the marketing data.
`[9] NovoLog Vial consists of drugs listed as "NovoLog" and "Insulin Asparl" in the marketing data.
`[1 O] Humalog Mix 75/25 Vial consists of the drug listed as "Humalog Mix 75/25" in the marketing data.
`[11] Humalog Mix 50/50 Vial consists of the drug listed as "Humalog Mix 50/50" in the marketing data.
`[12] Novo Log FlexPen Mix 70/30 consists of drugs listed as "Novo Log Mix 70/30 FlexPen" and "Novo Log Mix Flex Pen" in the marketing data.
`[13] Novo Log Mix 70/30 Vial consists of the drug listed as "Novo Log Mix 70/30" in the marketing data.
`[14] Basaglar KwikPen consists of the drug listed as "Basaglar" in the marketing data.
`[15] Lanius Vial consists of drugs listed as "Lanius" and "Insulin Glargine" in the marketing data.
`[16] Levemir FlexPen was discontinued in September 2014, the eighth year after launch. Data for Levemir FlexPen after September 2014 are excluded from this analysis.
`[17] Levemir Vial consists of drugs listed as "Levemir" and "Insulin Detemir" in the marketing data.
`[18] Toujeo SoloSTAR consists of drugs listed as "Toujeo" and "Toujeo SoloSTAR" in the marketing data.
`[19] Toujeo Max SoloSTAR consists of drugs listed as "Toujeo Max Solostar" in the marketing data.
`[20] Tresiba FlexTouch consists of drugs listed as "Tresiba," "Tresiba FlexTouch," and "Insulin Degludec" in the marketing data.
`
`DRAFT: 6/20/19
`
`Privileged and Confidential: Attorney Work Product
`
`Sanofi Exhibit 2205.002
`Mylan v. Sanofi
`IPR2018-01675
`
`